DarioHealth Corp (DRIO) Stock: Evaluating the Market Performance

Moreover, the 36-month beta value for DRIO is 1.66. Analysts have varying opinions on the stock, with 2 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”

The public float for DRIO is 23.91M and currently, short sellers hold a 5.60% of that float. On April 03, 2024, DRIO’s average trading volume was 135.11K shares.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

DRIO) stock’s latest price update

The stock price of DarioHealth Corp (NASDAQ: DRIO) has dropped by -10.14 compared to previous close of 1.48. Despite this, the company has seen a fall of -10.74% in its stock price over the last five trading days. Seeking Alpha reported 2023-10-03 that DarioHealth has experienced a disappointing year with stalled revenue growth and a decline in new customer wins. However, H2/23 and FY24 are expected to bring improved financials, including revenue growth, expanded gross margins, and declining operating expenses. The company’s competitive advantages include a customer-friendly platform, a multi-condition platform, and partnerships with important industry players.

DRIO’s Market Performance

DarioHealth Corp (DRIO) has experienced a -10.74% fall in stock performance for the past week, with a -33.33% drop in the past month, and a -22.67% drop in the past quarter. The volatility ratio for the week is 11.72%, and the volatility levels for the past 30 days are at 10.13% for DRIO. The simple moving average for the past 20 days is -15.17% for DRIO’s stock, with a -45.46% simple moving average for the past 200 days.

Analysts’ Opinion of DRIO

Many brokerage firms have already submitted their reports for DRIO stocks, with Alliance Global Partners repeating the rating for DRIO by listing it as a “Buy.” The predicted price for DRIO in the upcoming period, according to Alliance Global Partners is $8.75 based on the research report published on May 13, 2022 of the previous year 2022.

Cowen, on the other hand, stated in their research note that they expect to see DRIO reach a price target of $31. The rating they have provided for DRIO stocks is “Outperform” according to the report published on April 22nd, 2021.

Stifel gave a rating of “Buy” to DRIO, setting the target price at $30 in the report published on March 23rd of the previous year.

DRIO Trading at -29.24% from the 50-Day Moving Average

After a stumble in the market that brought DRIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -70.96% of loss for the given period.

Volatility was left at 10.13%, however, over the last 30 days, the volatility rate increased by 11.72%, as shares sank -23.56% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -42.17% lower at present.

During the last 5 trading sessions, DRIO fell by -10.74%, which changed the moving average for the period of 200-days by -67.56% in comparison to the 20-day moving average, which settled at $1.5473. In addition, DarioHealth Corp saw -22.67% in overturn over a single year, with a tendency to cut further losses.

Stock Fundamentals for DRIO

Current profitability levels for the company are sitting at:

  • -2.75 for the present operating margin
  • 0.29 for the gross margin

The net margin for DarioHealth Corp stands at 0.04. The total capital return value is set at -0.67. Equity return is now at value -79.57, with -50.99 for asset returns.

Based on DarioHealth Corp (DRIO), the company’s capital structure generated 0.33 points at debt to capital in total, while cash flow to debt ratio is standing at -1.06. The debt to equity ratio resting at 0.49. The interest coverage ratio of the stock is -33.61.

Currently, EBITDA for the company is -50.84 million with net debt to EBITDA at 0.15. When we switch over and look at the enterprise to sales, we see a ratio of 1.55. The receivables turnover for the company is 5.98for trailing twelve months and the total asset turnover is 0.21. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.77.

Conclusion

To wrap up, the performance of DarioHealth Corp (DRIO) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts